According to a Reuters article, the U.S.-India Business Council (USIBC) claimed that India will not grant licenses allowing local firms to override patents and make cheap copies of drugs by Western drugmakers.
The comments were given in a submission by the USIBC to the U.S. Trade Representative (USTR), which is reviewing global intellectual property laws for an annual report identifying trade barriers to U.S. companies, the story said.
The USTR says the country's patent laws unfairly favor local drug makers. Read the full article
